Kayla Cunningham
Endocrinology, Diabetes & Metabolism · San Francisco, CANPI 1609894534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,764 and has fallen 98.6% since, to $39 in 2025.
Across 281 payments — averaging $13.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$709
- Sanofi-aventis U.S. LLC$532
- Lilly USA, LLC$316
- Tandem Diabetes Care, Inc.$255
- AbbVie$230
- Insulet Corporation$210
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,779100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 128 | $709 |
| Sanofi-aventis U.S. LLC | 23 | $532 |
| Lilly USA, LLC | 20 | $316 |
| Tandem Diabetes Care, Inc. | 5 | $255 |
| AbbVie | 15 | $230 |
| Insulet Corporation | 12 | $210 |
| AstraZeneca(2 entities) | 11 | $198 |
| Abbott | 8 | $179 |
| Amneal Pharmaceuticals LLC | 5 | $152 |
| Boehringer Ingelheim | 9 | $142 |
| Amgen | 5 | $114 |
| Merck | 7 | $114 |
| Johnson & Johnson | 4 | $69 |
| Medtronic | 3 | $62 |
| Corcept Therapeutics | 2 | $58 |
| Eisai Inc. | 3 | $56 |
| BD | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $51 |
| Dexcom, Inc. | 1 | $42 |
| IBSA Pharma Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $35 |
| Companion Medical, Inc. | 2 | $34 |
| Pfizer | 2 | $25 |
| Valeritas, Inc. | 1 | $22 |
| Senseonics, Incorporated | 1 | $20 |
| Mission Pharmacal Company | 1 | $19 |
| Radius Health, Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$121
- Tresiba$121
- SOLIQUA 100/33$108
- TOUJEO$106
How this compares
$3,779 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in San Francisco
- Cheng Yang TuanSan Francisco$568K
- Lewis BlevinsSan Francisco$166K
- Wade AubrySan Francisco$79K
- Marc HellersteinSan Francisco$56K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.